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To investigate the effects of topically applied 17b-estradiol on the expression of extracellular matrix proteins in
aged human skin, 17b-estradiol (0.01%) and its vehicle (70% propylene glycol, 30% ethanol) were applied to aged
(68–82 y, eight females and ﬁve males) human buttock skin under occlusion for 2 wk (three times per week). Topical
17b-estradiol was found to increase the expression of type 1 procollagen mRNA and protein significantly in human
aged skin in vivo. In addition, MMP-1 protein levels were reduced by topical 17b-estradiol. The expressions of TGF-
b1, TGF-b type II receptor, and Sma and Mad related (Smad)3 were increased by topical 17b-estradiol in aged human
skin, and TGF-b1 neutralizing antibody inhibited 17b-estradiol-induced procollagen synthesis in cultured ﬁbro-
blasts. We also found that the expressions of tropoelastin and ﬁbrillin-1 mRNA and protein, and elastic ﬁbers in
aged skin were also increased by topical 17b-estradiol. Topical 17b-estradiol also increased keratinocyte prolif-
eration and the epidermal thickness in aged human skin. We also observed the same effects of topical 17b-estradiol
in young skin. In conclusion, our results suggest that topical 17b-estradiol treatment may improve the cutaneous
function of aged human skin by improving the connective tissue and increasing epidermal thickness.
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Cutaneous aging is the result of a combination of chrono-
logical and environmental (ultraviolet light, smoking, pollu-
tion) factors, and hormonal aging (Chung, 2003; Youn et al,
2003). In aged skin, epidermal thinning, associated with re-
duced numbers of keratinocytes, may be observed histo-
logically. The dermis also thins in aging skin, and results in a
reduction in the amount and organization of connective tis-
sue. Skin connective tissue is comprised primarily of fibrillar
collagen bundles and elastic fibers. Collagen and elastin
impart strength and resilience to skin, and their degenera-
tion with aging causes skin to become fragile, and aged in
appearance.
At present, most women in developed societies can ex-
pect to spend one-third or more of their lifetime in the
postmenopausal period. During the menopausal years, the
loss of estrogen production accelerates skin changes (Pun-
nonen et al, 1987; Jemec and Serup, 1989). The epidermis
becomes thinner and re-epithelialization is retarded. The
dermis also becomes thinner and loses its elasticity and
tensile strength. The skin wrinkling and increased looseness
of the skin after menopause correspond to changes in col-
lagenous and elastic fibers, which have been reported to be
owing to estrogen deficiency (Schmidt et al, 1994). A sig-
nificant reduction in skin collagen has been demonstrated
to start at menopause. This menopause-related reduction
shows a faster rate of loss during the initial postmenopausal
period, and approximately 30% is lost in the first 5 y (Brincat
et al, 1987b). The average rate of loss of skin collagen has
been reported to be 2.1% per postmenopausal year (Brin-
cat et al, 1987a).
Estrogen is a steroid hormone, which influences growth,
differentiation, and the functions of many target tissue.
There are three kinds of estrogen: E1 (estrone), E2 (estra-
diol), and E3 (estriol). E2 is the most functional estrogen
during reproductive age, and is known to decrease abruptly
after menopause. Skin tissue is an active target of estrog-
ens, as demonstrated by estrogen receptor determinations
(Schmidt et al, 1990). Moreover, a higher estrogen receptor
content has been reported in women (Ciocca and Roig,
1995). It was found that estrogen replacement therapy im-
proves the various symptoms of skin aging. For example,
oral estrogen therapy caused thickening of the skin in post-
menopausal women (Brincat et al, 1985; Maheux et al,
1994), prevented the age-related reduction in cutaneous
elasticity, thereby inhibiting skin slackness, and reducing
the number and depth of wrinkles (Pierard et al, 1995; Dunn
et al, 1997). Also, the topical application of estrogen cream
improved the external appearance of postmenopausal
Abbreviations: MMP, matrix metalloproteinases; PIC, anti-human
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facial skin, elasticity and firmness markedly improved, and
wrinkle depth and number decreased (Creidi et al, 1994;
Schmidt et al, 1996). These beneficial effects of estrogen
may result from increased collagen or other matrix proteins.
Many reports have found that skin collagen content in-
creases in women on estrogen replacement (Brincat, 2000;
Shah and Maibach, 2001). The molecular mechanism of
estrogen-induced increased collagen content has not been
investigated however.
Transforming growth factor (TGF-b) is a multifunctional
cytokine that plays an important role in regulating cell
growth, differentiation, and the biosynthesis of extracellular
connective tissue (Massague, 1990, 1998; Piek et al, 1999).
In mammals, TGF-b1, -b2, and -b3 isoforms have been
identified (Massague, 1990). TGF-b initiate their cellular ac-
tion by binding to cell surface receptors, TGF-b type I re-
ceptor (TbRI) and TGF-b type II receptor (TbRII). Upon
binding, the activated TGF-b receptor complex transiently
interacts with Sma and Mad related (Smad) proteins, intra-
cellular signal transducers, which propagate TGF-b signals
(Massague, 1998). TGF-b is known to stimulate fibroblast
proliferation in the dermis and induces the synthesis and
secretion of the major extracellular matrix (ECM) proteins
(Massague, 1998; Piek et al, 1999). In addition, TGF-b
downregulates the expressions of proteolytic enzymes,
such as collagenase and stromelysin, which degrade ex-
tracellular matrix proteins (Eickelberg et al, 1999; Hall et al,
2003). It has been reported that estrogen increases the
production of TGF-b, and that this inhibits bone resorption
in human osteoblast-like cells (Oursler et al, 1991) and rat
bone (Yang et al, 1996). It has also been reported that aging
in healthy females is associated with a reduced rate of cu-
taneous wound healing and that TGF-b1 levels are reduced
in the wound. In addition, it was found that the topical ap-
plication of estrogen accelerates cutaneous wound healing
by increasing TGF-b1 secretion by dermal fibroblasts in
ovariectomized young female rodents (Ashcroft et al, 1997).
Despite the important role of the TGF-b/Smad pathway
in extracellular matrix regulation, no study has been con-
ducted on the effects of topical 17b-estradiol on TGF-b
signaling activation in aged human skin in vivo. Moreover,
we still do not know the effects of topical estrogen on the
amount and organization of elastic fibers in aged skin or on
the expression of elastin and fibrillin-1, which are the major
components of elastic fibers. Therefore, this study was un-
dertaken to investigate the effects of topical 17b-estradiol
on the expressions of type I procollagen, tropoelastin, fi-
brillin-1, and matrix metalloproteinase (MMP)-1 in aged hu-
man skin in vivo, and to observe changes in the expressions
of 17b-estradiol-induced TGF-bs, TGF-b receptors, and
Smad proteins. Our data suggest that topical 17b-estradiol
improves cutaneous ECM alterations by stimulating the
TGF-b/Smad pathway in aged human skin, and that these
effects may ameliorate skin aging symptoms, such as skin
wrinkling and loss of elasticity.
Results
Topical application of 17b-estradiol increased the ex-
pressions of type I procollagen mRNA and protein in
aged human skin in vivo To investigate the effects of
topical 17b-estradiol on type I procollagen mRNA and pro-
tein expression in aged skin, the buttock skins of elderly
volunteers were treated with 0.01% 17b-estradiol or its ve-
hicle (70% propylene glycol, 30% ethanol) solution three
times per week for 2 wk (six times) under occlusion.
By RT-PCR analysis using total RNA extracted from
punch-biopsied skin samples, we found that the levels of
procollagen a1(I) mRNA in relation to glyceraldehyde-3-
phosphate dehydragenase (GAPDH) mRNA were increased
after topical 17b-estradiol (Fig 1a). Topical 17b-estradiol
significantly increased the expression of procollagen a1(I)
mRNA by an average of 158.3%  16.5% (n¼11, po0.001)
versus vehicle-treated control skin (Fig 1a).
We performed western blot analysis for type I procolla-
gen protein using the total protein extracted samples of
17b-estradiol or vehicle-treated skin. The levels of type I
procollagen protein in 17b-estradiol-treated skin were sig-
nificantly higher by 261.7%  43.8% (n¼13, po0.01) than
in vehicle-treated skin (Fig 1b). Interestingly, the increases in
the level of type I procollagen by topical 17b-estradiol
treatment in aged female skin (336.4%  55.7%, n¼8)
was significantly higher (po0.05) than in aged male skin
(142.3%  22.1%, n¼ 5). These results indicate that topical
17b-estradiol may increase the synthesis of type I procol-
lagen in aged human skin in vivo regardless of gender, and
that, however, this effect was significantly greater in aged
women than aged men. Thus, it appears that reduced est-
rogen levels with aging may contribute to reduced procol-
lagen synthesis in aged human skin in both aged women
and aged men.
To localize and compare the expressions of type I pro-
collagen protein in the 17b-estradiol or vehicle-treated skin,
we performed immunostaining with two kinds of antibodies
for type I procollagen. Anti-human procollagen type I C-
peptide (PIC) antibody stains strongly for intracellular pro-
collagen protein (Fig 2c, d), whereas anti-procollagen type 1
amino-terminal extension peptide (SP1.D8) antibody stains
extracellular procollagen proteins, especially beneath the
dermo-epidermal junction (Fig 2a, b). We found that the ex-
tracellular and intracellular expressions of type I procollagen
protein in the 17b-estradiol-treated skin (Fig 2b, d) were
greater than in vehicle-treated skin (Fig 2a, c). The number
of type I procollagen-positive fibroblasts stained with PIC
antibody in the upper dermis in 17b-estradiol-treated skin
(57.5  7.8 cells per  200 magnified microscopic field,
n¼6, po0.01) was significantly higher than in vehicle-treat-
ed skin (17.3  3.2 cells, n¼6) of the same individuals
(Fig 2e). In Masson’s trichome stained section, collagen
fiber bundles were increased and thickened in the upper
dermis of 17b-estradiol-treated skin, compared with vehicle-
treated skin (Fig 2f). In order to investigate the concen-
tration-dependent effects of topical 17b-estradiol on the
expression of type I procollagen expression in aged human
skin, the buttock skins of elderly volunteers were treated
with 0.001%, 0.003%, and 0.01% 17b-estradiol or its ve-
hicle (70% propylene glycol, 30% ethanol) solution for a
week (three times) under occlusion. By Quantitative real-
time RT-PCR, we found that 0.003% and 0.01%, but not
0.001%, topical 17b-estradiol significantly increased the
expression of procollagen a1(I) mRNA (n¼3), compared
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with vehicle-treated control skin (Fig 2g). We also found, by
immunohistochemical staining, that extracellular and intra-
cellular expressions of type I procollagen protein in the
0.003% and 0.01% 17b-estradiol-treated skin were in-
creased, compared with vehicle-treated skin (Fig 2h). This
observation suggests that topical 17b-estradiol treatment
can increase type I procollagen synthesis and restore col-
lagen fiber bundles in aged human skin in vivo.
Topical application of 17b-estradiol reduced MMP-1 pro-
tein expression in aged human skin in vivo To investi-
gate whether topical 17b-estradiol can regulate MMP-1
expression in aged skin, we compared MMP-1 protein ex-
pressions by western blot using the soluble protein fraction
extracted from 17b-estradiol or vehicle-treated skin of the
same individuals. We found that topical 17b-estradiol treat-
ment reduced MMP-1 protein expression significantly by
76.9%  3.9% versus vehicle-treated skin, in five of ten
elderly subjects (Fig 3). The decreases in the level of MMP-1
by topical 17b-estradiol treatment were not different be-
tween aged female and male skin (data not shown). This
result suggests that estrogen downregulation with aging
may contribute to increased MMP-1 expression in aged
human skin.
Topical 17b-estradiol increased TGF-b1 mRNA expres-
sion and protein in aged human skin in vivo The effect of
topical 17b-estradiol on TGF-b1 mRNA expression was in-
vestigated by RT-PCR, using the total RNA extracted di-
rectly from the punch-biopsy samples. The application of
17b-estradiol (0.01%) for 2 wk to aged buttock skin in-
creased the TGF-b1 mRNA level to 117.3%  8.8% versus
vehicle-treated skin (Fig 4a, n¼11, po0.05). There tended
to be higher expression of TGF-b1 mRNA induction in aged
female skin, compared with aged male skin, but it was not
statistically significant (data not shown). The PCR product
was isolated, sequenced, and found to be identical to the
TGF-b1 cDNA fragment (data not shown).
By immunohistochemical staining, we found that topical
17b-estradiol increased the expressions of TGF-b1, -b2,
and -b3 proteins in the aged human skin (Fig 4b, n¼5). In
control skin, TGF-b1 protein was present minimally in the
epidermis and dermis, whereas TGF-b2 and -b3 were
stained moderately in the lower epidermis and in some
dermal cells (Fig 4b). Topical 17b-estradiol increased not
only TGF-b1 staining, which was primarily localized in the
dermis, but also TGF-b2 and -b3 staining, which primarily
localized in the epidermis. These results indicate that top-
ical 17b-estradiol upregulates TGF-b1 expression in aged
skin, which may increase the synthesis of procollagen and
the inhibition of MMP-1 in aged skin.
Anti-TGF-b1 antibody inhibited 17b-estradiol-induced
type I procollagen synthesis in cultured human dermal
ﬁbroblasts In order to investigate whether TGF-b1 medi-
ates 17b-estradiol-induced type I procollagen synthesis,
anti-human TGF-b1 antibody was added to a dermal fibro-
blast culture medium just before 17b-estradiol was added,
and media were harvested 48 h later. Type I procollagen
levels were measured in cell-free supernatants using a
commercially available ELISA kit.
The 17b-estradiol (1 mM) was found to increase the syn-
thesis of type I procollagen protein to 132.1%  2.2%
(po0.01), compared with the control. On the other hand,
TGF-b1 (10 ng per mL) increased type I procollagen
protein to 162.7%  9.2% (po0.01), compared with the
vehicle control. The addition of 1 or 3 mg per mL of anti-
human TGF-b1 antibody inhibited 17b-estradiol-induced
type I procollagen synthesis concentration-dependently to
119.9%  9.0% (p40.05) and 104.6%  8.4% (po0.05)
of the vehicle-treated control, respectively (Fig 5). These
results suggest that TGF-b may mediate, at least in part,
17b-estradiol-induced procollagen synthesis in human fib-
roblasts.
The topical application of 17b-estradiol increased the
expression of TbRII, but not of TbRI, in aged human skin
in vivo It has been reported that the expressions of TbRI
and TbRII are downregulated in aged fibroblasts in vitro, and
that the expression of TbRII is also reduced in aged skin
in vivo (Mori et al, 1998; Rittie and Fisher, 2002). Therefore,
we investigated whether 17b-estradiol application can af-
Figure 1
The expression of type I pro-
collagen mRNA and protein in-
creased after topical 17b-estra-
diol application to aged human
skin in vivo. Buttock skin of elderly
volunteers (five men, mean age
76.2 y, age range 75–79 y; eight
women, mean age 73.2 y, age
range 62–78 y) were treated with
0.01% 17b-estradiol or its vehicle
(70% propylene glycol, 30% et-
hanol) solution three times a week
for 2 wk (six times) under occlu-
sion. The skin samples were ob-
tained by punch biopsy. (a) The
levels of procollagen a1(I) mRNA
were measured in the total RNA
extracted from buttock skin (n¼11)
by RT-PCR. Data are expressed as
ratios of procollagen a1(I) to GAPDH, and as percentage increases relative to vehicle-treated skin. (b) The levels of type I procollagen protein were
measured in total proteins extracted from aged buttock skin (n¼13) by western blot. Data are expressed as ratios of type I procollagen to b-actin,
and as percentage increases relative to vehicle-treated skin. Values are means  SEM. Insets show representative RT-PCR and western blot bands,
respectively. po0.01, po0.001 versus vehicle-treated control skin.
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fect the expressions of TbRII and TbRI. The effects of top-
ical 17b-estradiol on TbRII and TbRI mRNA expression were
investigated by RT-PCR, using the total RNA extracted di-
rectly from the punch-biopsy samples (n¼ 10). Topical ap-
plication of 17b-estradiol (0.01%) to skin increased the
TbRII mRNA level by an average of 180%  57.1% (n¼10,
po0.05), compared with vehicle-treated control skin (Fig
6a), but did not affect the TbRI mRNA level (data not
shown). There was no significant difference in TbRII mRNA
induction between aged female and male skin (data not
shown). The PCR products were isolated, sequenced, and
found to be identical to the TbRII and TbRI cDNA fragments
(data not shown).
We found by immunohistochemical staining that topical
17b-estradiol upregulated TbRII protein in the epidermis
and dermis of aged human skin (Fig 6b, n¼7). The immuno-
reactivity for TbRI protein was, however, unaffected by 17b-
estradiol treatment (Fig 6b, n¼ 7). These results indicate
Figure 2
Topical application of 17b-estradiol increased the expression of type I procollagen protein and collagen fibers in aged human skin in vivo.
17b-Estradiol (0.001%, 0.003%, 0.01%) or its vehicle (70% propylene glycol, 30% ethanol) were applied to the buttock skin of elderly subjects under
occlusion. (a, b, h) The extracellular expression of type I procollagen was detected using SP1.D8 antibody, and (c, d, h) the intracellular expression of
type I procollagen protein in fibroblasts was detected using PIC antibody by immunohistochemical staining. (e) The number of fibroblasts expressing
type I procollagen protein in the upper dermis was counted. Values are means  SEM per  200 field of six subjects. The photographs are
representative of six subjects. po0.01. (f) Masson’s trichome staining of collagen fiber bundles (n¼5). (g) The levels of procollagen a1(I) mRNA
were measured in the total RNA extracted from buttock skin (n¼ 3) by real-time RT-PCR.
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that the 17b-estradiol treatment increased TGF signaling
activity by upregulating TbRII expression.
Topical application of 17b-estradiol increased the ex-
pressions of Smad3 and Smad7 in aged human skin
in vivo Smad transcription factors are intracellular media-
tors of TGF-b signaling and have been shown to mediate
the effects of TGF-b on the deposition of extracellular matrix
(Verrecchia and Mauviel, 2002). Therefore, we investigated
the effect of topical 17b-estradiol on Smad3 expression,
which is a receptor-activated Smad and is directly activated
by TGF-b to TbRII binding, and on Smad7 expression,
which is an inhibitory Smad, which performs a negative
feedback function in TGF-b signaling. Topical 17b-estradiol
increased Smad3 mRNA to 191%  51.9% (Fig 7a, n¼5)
and induced Smad7 mRNA expression significantly to
127%  9.3% (Fig 7c, n¼ 7, po0.05) versus vehicle-treat-
ed skin. We also found that topical 17b-estradiol increased
Smad3 protein to 113.6%  9.9% (Fig 7b, n¼ 7), but
Smad7 protein was not detected by western blot analysis
in this study (data not shown).
Figure 3
The expression of matrix metalloproteinase (MMP)-1 protein de-
creased after topical 17b-estradiol application to aged human skin
in vivo. The expression of MMP-1 protein was measured by western
blot using the soluble protein fraction extracted from the 17b-estradiol
or vehicle-treated buttock skins of the same elderly individuals (n¼ 10).
po0.01, versus vehicle-treated control skin. Mean  SEM.
Figure 4
Levels of TGF-b1 mRNA
and protein were elevat-
ed after topical 17b-est-
radiol treatment in aged
human skin in vivo. (a)
The level of TGF-b1 mRNA
was measured in total
RNA extracted from 17b-
estradiol or vehicle-treat-
ed buttock skin of the
same elderly individuals
by RT-PCR (n¼ 11). Data
are expressed as ratios of
TGF-b1 to GAPDH, and as
percentage increases rel-
ative to vehicle-treated
skin. Values are mean-
s  SEM. Insets show
representative RT-PCR.
po0.05. (b) Immuno-
histochemical staining of
TGF-b1, -b2, and-b3. The
photographs are repre-
sentative of seven elderly
subjects.
Figure5
17b-Estradiol-induced type I procollagen synthesis was inhibited
by adding neutralizing TGF-b1 antibody to cultured human dermal
fibroblasts. Neutralizing anti-human TGF-b1 antibody (1–3 mg per mL)
was added to dermal fibroblast culture medium just before 17b-est-
radiol treatment (1 mM), and culture media were harvested 48 h later.
Type I procollagen levels were measured in cell-free supernatants by
ELISA. po0.05 versus vehicle-treated control fibroblasts, ypo0.05
versus 17b-estradiol-treated fibroblasts. Values are means  SEM. The
graph shown is representative of three experiments.
17b-ESTRADIOL INCREASES ECM PROTEINS 1153124 : 6 JUNE 2005
Topical 17b-estradiol increased the expressions of
tropoelastin and ﬁbrillin-1 in aged human skin
in vivo We also investigated the effects of topical 17b-est-
radiol on the mRNA expression of tropoelastin and fibrillin-1
in aged human skin in vivo. RT-PCR was performed using
the total RNA extracted from the punch-biopsied samples
of 17b-estradiol and vehicle-treated skin. Tropoelastin
mRNA expression was increased to 122%  12.4%
(n¼ 11, po0.05) in 17b-estradiol-treated skin, compared
with vehicle-treated skin (Fig 8a). Topical 17b-estradiol also
increased the expression of fibrillin-1 mRNA to 182.1% 
44% (n¼11, po0.01), compared with vehicle-treated skin
(Fig 8b). There were no significant differences in tropoelastin
and fibrillin-1 mRNA induction between aged female and
male skin (data not shown).
Immunohistochemical staining showed that anti-tro-
poelastin and anti-fibrillin-1 antibodies stained fine ascend-
ing fibers (oxytalan fibers) in the papillary dermis beneath
the dermoepidermal junction, and elaunin and elastic fibers
in the mid-dermis (Fig 8c, d). We observed that the immun-
oreactivities of tropoelastin and fibrillin-1 protein were in-
creased by 17b-estradiol treatment in aged skin versus
vehicle-treated skin, and most of the immunoreactivity of
both proteins was present in association with elastic fibers.
The numbers and lengths of elastin- and fibrillin-1-immuno-
reactive elastic fibers were greater in 17b-estradiol-treated
skin than in the vehicle-treated skin of the same individuals
(Fig 8c, d). This observation suggests that topical 17b-est-
radiol treatment can increase and restore elastic fibers in
aged human skin in vivo.
Figure6
Topical application of 17b-est-
radiol upregulated TGF-b type
II receptor (TbRII), but not
TGF-b type I receptor (TbRI)
expression, in aged human
skin in vivo. (a) Levels of TbRII
mRNA were measured in the
total RNA extracted from the
17b-estradiol or vehicle-treated
buttock skin of the same elderly
individuals by RT-PCR (n¼10).
Data are expressed as ratios of
TbRII to GAPDH, and as per-
centage increases relative to
vehicle-treated skin. Values
shown are means  SEM. In-
sets show representative RT-
PCR. po0.05. (b). Immuno-
histochemical staining of TbRI
and TbRII. The photographs
shown are representative of five
elderly subjects.
Figure 7
Topical application of 17b-estradiol increased the expressions of Sma and Mad related (Smad)3 and Smad7 mRNA in aged human skin in
vivo. The levels of (a),(b) Smad3 and (c) Smad7 mRNA were measured in the total RNA extracted from 17b-estradiol or vehicle-treated buttock skin
of the same elderly individuals by RT-PCR. Data are expressed as ratios of Smad3 (n¼ 5) or Smad7 (n¼7) to GAPDH, respectively, and as
percentage increases relative to vehicle-treated skin. The values shown are means  SEM. Insets show representative RT-PCR. po0.05.
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Figure 8
Topical 17b-estradiol increased the expressions of tropoelastin and fibrillin-1 and restored elastic fiber in aged human skin in vivo. The
levels of (a) tropoelastin and (b) fibrillin-1 mRNA were measured in total RNA extracted from the 17b-estradiol or vehicle-treated buttock skin of the
same elderly individuals by RT-PCR (n¼ 11). Data are expressed as ratios of tropoelastin or fibrillin-1 to GAPDH and as percentage increases relative
to vehicle-treated skin. The values shown are means  SEM. Insets show a representative RT-PCR. po0.05, po0.01. Immunohistochemical
staining of (c) tropoelastin and (d) fibrillin-1. The photographs are representative of five elderly subjects.
Figure 9
Topical application of 17b-estradiol in-
duced keratinocyte proliferation and
increased epidermal thickness in aged
human skin in vivo. (a) Immunohisto-
chemical staining of 17b-estradiol- and
vehicle-treated skin samples was per-
formed using anti-Ki67 antibody (n¼5).
(b) Entire section fields were counted at
 200, and the mean number of Ki-67
positive keratinocytes per mm of the ep-
idermis calculated. (c) Average epidermal
thickness was determined using an image
analyzer. po0.05, po0.01.
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The topical application of 17b-estradiol-induced kera-
tinocyte proliferation and increased epidermal thick-
ness in aged human skin in vivo We found that topical
17b-estradiol increased the number of Ki-67 positive kera-
tinocytes in the basal cell layer of the epidermis and
increased epidermal thickness, compared with vehicle-
treated skin (Fig 9). The topical application of 0.01% 17b-
estradiol to aged human skin (three times a week for 2 wk
under occlusion) increased the number of Ki-67 positive
keratinocytes in the basal cell layer significantly (145  48.7
cells per mm, n¼ 5, po0.01) versus control skin (74  4.2
cells per mm) (Fig 9a, b). And, the epidermal thickness of
the 17b-estradiol treated skin was also significantly greater
to 133.8%  10.4% (n¼ 5, po0.05) versus control skin
(Fig 9a, c). These results indicate that topical 17b-estradiol
can stimulate keratinocyte proliferation in aged human skin,
and that this results in a greater epidermal thickness in vivo.
The effects of topical 17b-estradiol in young human skin
in vivo In order to investigate whether topical 17b-estradiol
is also effective in young skin or not, the buttock skins of
young volunteers were treated with 0.01% 17b-estradiol or
its vehicle (70% propylene glycol, 30% ethanol) solution
three times per week for 2 wk (six times) under occlusion.
Topical 17b-estradiol significantly increased the ex-
pression of procollagen a1(I) mRNA by an average of
263.7%  65.0% (n¼ 4, po0.05) (Fig 10a), and the number
of type I procollagen-positive fibroblasts in the upper dermis
in 17b-estradiol-treated skin was significantly increased
than in the case of vehicle-treated skin of the same young
individuals (Fig 10d). Topical 17b-estradiol increased the
mRNA expression of tropoelastin (117.3%  21.6%, n¼4)
(Fig 10b) and fibrillin-1 (156.3%  35.8%, n¼4, po0.05)
(Fig 10c) in 17b-estradiol-treated young skin, compared
with vehicle-treated skin. The numbers and lengths of el-
astin-and fibrillin-1-immunoreactive elastic fibers were in-
creased in 17b-estradiol-treated young skin, compared with
the vehicle-treated skin of the same individuals (Fig 10e, f).
Topical 17b-estradiol increased significantly the expres-
sions of TGF-b1 (Fig 11a), TbRII (Fig 11b), Smad3 (Fig 11c),
and Smad7 (Fig 11d) in young human skin.
Discussion
The skin aging process in the sun-protected skin of the
elderly results in a loss of collagen and increased MMP-1
expression (Varani et al, 2000; Chung et al, 2002). We found
that topical 17b-estradiol applied to aged human skin in-
creased the expressions of type I procollagen mRNA and
protein. Although there were individual variations of re-
sponses to estradiol, 0.003% and 0.01%, but not 0.001%,
Figure 10
Topical 17b-estradiol increased the expressions of type I procollagen, tropoelastin and fibrillin-1 in young human skin in vivo. The levels of
(a) type I procollagen, (b) tropoelastin, and (c) fibrillin-1 mRNA were measured in total RNA extracted from the 17b-estradiol or vehicle-treated
buttock skin of the same young individuals by RT-PCR (n¼ 4). Data are expressed as ratios of type I procollagen, tropoelastin, or fibrillin-1 to GAPDH
and as percentage increases relative to vehicle-treated skin. The values shown are means  SEM. Insets show a representative RT-PCR. po0.05,
Immunohistochemical staining of (d) type I procollagen, (e) tropoelastin, and (f) fibrillin-1. The photographs are representative of four young subjects.
1156 SON ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
estradiol significantly increased the type I procollagen
mRNA and protein expression in a concentration-depend-
ent manner. 0.003% of estradiol tended to increase type I
procollagen expression more than 0.01%. Our results are
consistent with previous reports, which demonstrate that
topical and systemic estrogen therapy can increase the skin
collagen content, and help maintain skin dermal thickness
and reduce skin wrinkling (Creidi et al, 1994; Maheux et al,
1994). Climacteric skin aging is an entity distinct from in-
trinsic aging and photoaging. It is well known that the
amount of skin collagen declines in the years following
menopause owing to estrogen deficiency (Brincat et al,
1987a; Castelo-Branco et al, 1994). Moreover, this post-
menopausal reduction in skin collagen content may aggra-
vate facial wrinkle formation in postmenopausal women
(Youn et al, 2003). This menopause-related decrease of
collagen is not limited to skin, but is also observed in the
bone and urinary tract, and contributes to the pathogeneses
of osteoporosis and stress incontinence (Brincat et al,
1987b). Furthermore, we observed that topical 17b-estra-
diol stimulated the synthesis of type I procollagen synthesis
much more so in aged female skin. Our data suggest that
the abrupt estrogen level reduction in postmenopausal
women may accelerate age-dependent reduced collagen
synthesis, leading to greater collagen deficiency in elderly
women than in men; conversely, the response rate to topical
17b-estradiol treatment may be more rapid and prominent
in postmenopausal women than in men. On the other hand,
we could not see any significant differences between fe-
males and males in the other measurements, including
MMP, TGF-b, TbRII, tropoelastin, and fibrillin-1. This dis-
crepancy may be owing to the small number of volunteers
of male and females who participated in each experiment,
but further study is necessary to investigate these differ-
ences.
TGF-b is a major regulator of the synthesis of several
extracellular matrix proteins. TGF-b has been shown to up-
regulate the production of type I, III, and VII collagens (Uitto
et al, 1979; Massague, 1998; Vindevoghel et al, 1998), and
fibronectin (Hocevar et al, 1999), and to regulate the ex-
pressions of several MMP including MMP-1, -2, -3, and -13
(Kubota et al, 1991; Uria et al, 1998). TGF-b1 has also been
shown to be downregulated in in vitro aged fibroblasts and
in aged skin in vivo (Zeng et al, 1996; Mori et al, 1998; Rittie
and Fisher, 2002). Therefore, it is reasonable to speculate
that the aging-related impairment of the TGF-b/Smad path-
way may play a role in reducing collagen synthesis and
increasing MMP-1 expression, and that 17b-estradiol-in-
duced collagen synthesis and MMP-1 inhibition occur
through the stimulation of TGF-b signaling by topical 17b-
estradiol. In this study, we found that the topical application
of 17b-estradiol increased the expression of TGF-b1 in aged
human skin, and that neutralizing anti-TGF-b1 antibody can
prevent increased type I procollagen production by 17b-
estradiol in cultured fibroblasts. Our results indicate that the
increased level of TGF-b1 by topical 17b-estradiol in aged
human skin may mediate 17b-estradiol-induced collagen
synthesis.
TGF-b initiates its signals by interacting with its recep-
tors. The binding of TGF-b to TbRII results in the formation
of a heteromeric complex between TbRI and TbRII, which
results in the phosphorylation of TbRI by TbRII. Binding of
Figure 11
Topical 17b-estradiol upregulated the
expressions of TGF-b1, TGF-b type II
receptor (TbRII), Sma and Mad related
(Smad)3, and Smad7 mRNA in young
human skin in vivo. The levels of (a) TGF-
b1, (b) TbRII, (c) Smad3, and (d) Smad7
mRNA were measured in the total RNA
extracted from 17b-estradiol or vehicle-
treated buttock skin of the same young
individuals (n¼4) by RT-PCR. Data are
expressed as ratios of TGF-b1, TbRII,
Smad3, or Smad7 to GAPDH and as
percentage increases relative to vehicle-
treated skin. The values shown are mean-
s  SEM. Insets show representative RT-
PCR. po0.05, po0.01.
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TGF-b to TbRII is the first critical step in the TGF-b signaling
cascade, because TbRI does not bind TGF-b directly (Laiho
et al, 1991; Wrana and Attisano, 2000). TbRI phosphorylates
and activates the transcription factors Smad2 and Smad3,
which then bind with their common partner, Smad4, to form
a heteromeric complex that translocates to the nucleus,
where it acts as a transcription factor (Verrecchia and Mau-
viel, 2002). It has been reported that TbRI and TbRII are
downregulated in in vitro aged fibroblasts and that the
expression of TbRII is also reduced in aged skin (Zeng et al,
1996; Mori et al, 1998; Rittie and Fisher, 2002). In this study,
we found that topical 17b-estradiol increased the expres-
sions of TbRII mRNA and protein in aged human skin. In
contrast to TbRII, no significant changes were observed
with respect to TbRI mRNA and protein expression after
topical 17b-estradiol. Taken together, our data indicate that
17b-estradiol increases cellular responsiveness to TGF-b in
aged human skin by two mechanisms, i.e., by increasing
TGF-bs expression and by up-regulating TbRII. Further
studies are needed to clarify the mechanisms by which 17b-
estradiol upregulates TGF-b and TbRII expression. It has
been shown that type I and type VII collagen gene expres-
sion upregulation by TGF-b involve the direct binding of
Smad3 to specific Smad-binding elements in the respective
promoters (Vindevoghel et al, 1998; Chen et al, 1999). In
particular, the transient overexpression of Smad3 in normal
fibroblasts mimicked the effect of TGF-b on collagen gene
transcription. In addition, inhibiting cellular Smad3 expres-
sion, or its binding to its cognate DNA recognition site within
the type I collagen (COL1A2) promoter prevented the stim-
ulation of COL1A2 transcription by TGF-b (Chen et al, 2000).
These finings indicate that endogenous Smad3 is necessary
and sufficient for the stimulation of collagen production by
TGF-b in skin fibroblasts. Importantly, Smad3 plays a part in
multiple TGF-b-regulated responses, including the stimula-
tion of collagens (Vindevoghel et al, 1998), the synthesis of
connective tissue growth factor (CTGF) (Holmes et al, 2001),
the suppression of MMP-1 gene expression (Yuan and
Varga, 2001), and the induction of MMP-13 expression (Le-
ivonen et al, 2002). Our results show that topical 17b-est-
radiol increases the expression of Smad3 in aged skin,
suggesting that upregulation of Smad3 may be involved in
the 17b-estradiol-elicited induction of type I procollagen
and in the inhibition of MMP-1 expression in aged human
skin in vivo.
The actions of TGF-b are antagonized by Smad7, which
interacts with TbRI to prevent phosphorylation and activa-
tion of the receptor-regulated Smad2/3, thereby blocking
TGF-b signaling. Moreover, the expression of Smad7 is in-
duced by TGF-b itself, suggesting that the induction of en-
dogenous Smad7 serves as a negative feedback function in
TGF-b signaling (Whitman, 1997). Therefore, it is possible
that Smad7 expression in 17b-estradiol-treated aged skin is
induced in response to TGF-b1 induction and Smad3 ac-
tivation, to cause the autoinhibition of TGF-b signaling.
Elastin and fibrillin-1 are the main components of elastic
fibers and confer the skin with an elastic property. Histo-
logic findings of aged human skin show a general reduction
in the extracellular matrix with reduced elastin and elastic
fiber disintegration (Braverman and Fonferko, 1982). In the
present study, topical 17b-estradiol treatment increased
tropoelastin and fibrillin-1 mRNA expression in aged human
skin in vivo. We also found, by immunohistochemical stain-
ing, that the expressions of tropoelastin and fibrillin-1 pro-
teins were increased by topical 17b-estradiol, and that this
was mainly associated with elastic fibers. This report de-
scribes the stimulatory effects of topical 17b-estradiol on
elastin and fibrillin-1 expression in aged skin. It was pre-
viously reported that TGF-b1 up-regulates elastin gene
expression (Massague, 1998) and increases fibrillin-1 ex-
pression (Lorena et al, 2004). Therefore, our data suggest
that the 17b-estradiol-induced stimulation of TGF-b signa-
ling may upregulate elastin and fibrillin-1 mRNA and protein
expression in aged skin, and that this results in an increase
and a restoration of elastic fibers in aged skin.
The epidermis of human skin becomes thinner with a loss
of rete ridges with age. Moreover, it has been observed that
oral estrogen therapy causes a thickening of the epidermis
in castrated women (Brincat, 2000). In this study, the topical
application of 17b-estradiol to aged human skin increased
the proliferation of epidermal keratinocytes, leading to a
thickening of the epidermis. The biological effects of TGF-b
are diverse and strongly dependent on cell type. In human
skin, TGF-b inhibits the growth of epidermal keratinocytes
and stimulates the growth of dermal fibroblasts (Massague,
2000). Therefore, the 17b-estradiol-induced expression of
TGF-b observed in this study may not be involved in the
epidermal thickness caused by 17b-estradiol, and further
study will be needed to understand the molecular mecha-
nisms of epidermal thickness by topical 17b-estradiol. Re-
cently, it has been suggested that 17b-estradiol stimulates
keratinocyte proliferation by activation of ERK and also
by modulating nuclear estrogen receptor levels (Verdier-
Sevrain et al, 2004).
We demonstrated that topical application of 17b-estra-
diol to young skin also increased the expression of extra-
cellular matrix proteins, including type I procollagen,
tropoelastin and fibrillin-1, and increased the TGF-b/Smad
signaling by stimulating the expression of TGF-b1, TbRII,
and Smad3 in the young skin. Estrogen affects target tissue
function by binding to intracellular nuclear receptors, ER-a
and ER-b, and also membrane-associated ER (Verdier-Sev-
Figure12
Anti-skin aging effect of topical 17b-estradiol in aged human skin
in vivo.
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rain et al, 2004). Estrogens may maintain or even increase
the cell function by modulating receptor levels, and estro-
gen depletion with aging may reduce the cell functions.
Therefore, topical 17b-estradiol in both young and aged
skin can stimulate the extracellular matrix protein expres-
sion by binding to ER, and the effects may be greater
in aged skin by repairing estrogen deficiency in aged
skin.
In conclusion, this study shows that the topical applica-
tion of 17b-estradiol upregulates type I procollagen,
tropoelastin, and fibrillin-1, and downregulates MMP-1 ex-
pression by stimulating the TGF-b/Smad signaling pathway,
and that it increases the proliferation of epidermal keratin-
ocytes in aged human skin in vivo (Fig 12). Therefore, topical
17b-estradiol treatment may improve the cutaneous func-
tion of aged skin by improving the amounts and the organ-
ization of connective tissues and by increasing epidermal
thickness.
Materials and Methods
Human skin samples A total of 16 elderly (eight men; age range
62–79 y, mean age 73.5 y; eight women; age range 68–82 y, mean
age 73.2 y) and four young (four men; age range 31–34 y, mean age
33.3 y) Koreans, without current or prior skin diseases, provided
skin samples. 17b-estradiol (0.001%–0.01%) or its vehicle (70%
propylene glycol, 30% ethanol) was applied to the buttock skin
three times a week for 2 wk under occlusion. Skin samples were
obtained by punch biopsy at 2 d after the last treatment. Spec-
imens for western blotting and RT-PCR analysis were snap frozen
in liquid nitrogen, and specimens for immunohistochemical stain-
ing were oriented immediately in a cryomatrix (Shandon, Pitts-
burgh, Pennsylvania) and stored at 701C.
This study was conducted according to the Declaration of Hel-
sinki Principles. All procedures involving human subjects received
prior approval from the Seoul National University Institutional Re-
view Board, and all subjects provided written informed consent.
Fibroblast cell culture Primary cultures of dermal fibroblasts
were established from human adult foreskins in Dulbecco’s mod-
ified eagle medium (DMEM) supplemented with 10% fetal calf se-
rum, 2 mM glutamine, penicillin (100 U per mL), and streptomycin
(100 ug per mL) in a 371C humidified 5% CO2 incubator. The fib-
roblasts were cultured until 90% confluent and then subcultivated.
Cells cultured 4five passages were used for the experiments.
Immunohistochemical staining Serial sections of 5 mm thickness
were mounted onto silane-coated slides (Dako, Glostrup, Den-
mark). Acetone-fixed frozen sections were stained with the follow-
ing primary antibodies for 1h at room temperature: monoclonal
anti-human PIC antibody (Takara, Shiga, Japan, 1:1000), mono-
clonal anti-procollagen type I aminoterminal extension peptide
(SP1.D8) antibody (Developmental studies Hybridoma Bank, Iowa
City, Iowa, 1:1000), anti-fibrillin-1 antibody (Neomarker, Fremont,
California, 1:200), anti-tropoelastin antibody (EPC, Owensville,
Missouri, 1:800), anti-TGF-b1, -b2 and -b3 antibody (Oncogene,
San Diego, California, 1:100 dilution), anti-TbRI and anti-TbRII
antibody (Oncogene, 1:100 dilution), and anti-Ki-67 antibody
(Immunotech, Marseille Cedex, France, 1:1600). After rinsing in
phosphate-buffered saline, the sections were visualized using an
LSAB kit (Dako), which incorporates a biotinylated secondary an-
tibody and horseradish-streptavidine conjugate. 3-Amino-9-ethyl-
carbazole was used as a chromogenic substrate. The sections
were counterstained briefly in Mayer’s hematoxylin. Control stain-
ing was performed with normal rabbit and mouse immunoglobulin
and showed no immunoreactivity (data not shown).
The entire field of each section was examined at  400 mag-
nification, the number of fibroblasts showing positive immuno-
staining for type I procollagen in the papillary dermis was counted,
and the mean per  400 field calculated. The mean number of Ki-
67 positive keratinocytes per millimeter in the epidermis was de-
termined at  200, and the average thickness of the epidermis
was determined using an image analyzer (IMTechnology, Daejeon,
Korea).
Western blotting For western blotting, we used soluble protein
extracted directly from the punch-biopsied skin samples, as de-
scribed previously (Chung et al, 2000). Skin samples were sol-
ubilized in lysis buffer (containing 1% Triton X-100, 150 mM NaCl,
5 mM ethylenediamine tetraacetic acid, 0.1 mM dithiothreitol,
1 mM phenylmethylsulfonyl fluoride, 1 mg per mL aprotinin, and 2 mg
per mL leupeptin). After solubilizing, samples were incubated for
30 min on ice and then centrifuged at 13,000  g for 15 min at 41C.
Total protein concentrations were measured using a BCA protein
assay kit (Pierce, Rockford, Illinois). Type I procollagen, MMP-1
and Smad3 levels were determined using a monoclonal anti-pro-
collagen type I aminoterminal extension peptide (SP1.D8, 1/10 di-
lution) antibody, anti-MMP-1 antibody (Oncogene,1/100 dilution),
and anti-Smad3 antibody (Zymed, San Francisco, California, 1/
100), respectively. The density of each band was quantified by
densitometric analysis (AAB Soft Program, Fullerton, California).
RNA isolation and RT-PCR RT-PCR was performed as described
previously (Seo et al, 2001). Briefly, total RNA from human skin was
extracted with Trizol (Invitrogen, Carlsbad, California) according to
the manufacturer’s protocol. Total RNA was reverse-transcribed
using a 1st strand cDNA synthesis kit (Fermentas, Hanover, Mar-
yland) for RT-PCR. The resulting specific cDNA fragments were
amplified with 2.5 U of Taq polymerase (Bioneer, Daejeon, Korea) in
Table I. RT-PCR primers
Gene Primer sequence
Size
(bp)
GAPDH 50-ATTGTTGCCATCAATGACCC-30 (sense) 546
50-AGTAGAGGCAGGGATGATGT-30
(antisense)
Type I
procollagen
50-CTCGAGGTGGACACCACCCT-30 366
50-CAGCTGGATGGCCACATCGG-30
Fibrillin-1 50-GGTGAATGTACAAACACAGTCAGCAG-30 274
50-ATAGGAACAGAGCACAGCTTGTTGA-30
Tropoelastin 50-AAAGCAGCAGCAAAGTTCGG-30 288
50-ACCTGGGACAACTGGAATCC-30
TGF-b1 50-GCCCTGGACACCAACTATTGC-30 161
50-AGGCTCCAAATGTAGGGGCAGG-30
TbRI 50-AAGGGCAAAGGAGTTGGATT-30 303
50-AATCCCATTTTGAAGGCATG-30
TbRII 50-TTCAAGTGACAGGCATCAGC-30 233
50-CAGCAGCTCTGTGTTGTGGT-30
Smad7 50-CAACTTCTTCTGGAGCCTGG-30 475
50-CAAAGCTGATCTGCACGGTA-30
Smad3 50-CAAGTATGGTAGGGGAGGGC-30 241
50-CAGACGCCATTTCTTGCC-30
TbRI, TGF-b type I receptor; TbRII, TGF-b type II receptor; Smad, Sma
and Mad related.
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the presence of 20 pmol downstream and upstream primers for
each target gene. The sequences of each primer and the sizes of
the respective PCR products are shown at Table I. The cycle num-
bers used for tropoelastin (34 cycles), type I procollagen (25 cycle),
Smad3 and Smad7 (28 cycles), TGF-b1 (18 cycles), TbRI (32 cy-
cles), TbRII (32 cycles) fibrillin-1 (30 cycles), and GADPH (27 cy-
cles) were in the linear amplification range (data not shown). For
each sample studied, several negative controls were performed.
Reaction products were subjected to electrophoresis on 1.2% ag-
arose gel, visualized with EtBr, and signal strengths were quantified
using a densitometric program (AAB Software). After normalizing
versus GAPDH intensity, percentage increases were determined
for each gene. Each experiment was repeated at least three times.
Quantitative real-time RT-PCR Total RNA was extracted from
tissues using Trizol (Invitrogen), and 1 mg of total RNA was con-
verted to cDNA using First Strand cDNA Synthesis Kit (Fermentas).
Quantitation of procollagen a1(I) cDNA and endogeneous refer-
ence GAPDH cDNA was performed using a fluorescence detection
method (ABI PRISM 7000 Sequence Detection System, Perkin-
Elmer Applied Biosystems, Foster City, California). Sequence-spe-
cific PCR primer sets and TaqMan MGB probe (FAM dye-labeled)
were purchased by Perkin-Elmer Applied Biosystems. Cycling
conditions were 501C for 2 min, 951C for 10 min, followed by 40
cycles at 951C for 15 s and 601C for 1 min. To quantify the relative
changes in gene expression between each sample, we used the
comparative CT method, as previously described by Livak and
Schmittgen (2001). In the comparative CT method, the DCT mean
value obtained in the vehicle-treated sample is 0 and the fold dif-
ference is 1.
ELISA assay for type I procollagen protein Type I procollagen
protein levels in supernatant were determined by ELISA (Takara,
Shiga, Japan). Supernatants of cultured dermal fibroblast treated
with 17b-estradiol in the presence of anti-TGF-b1 antibody (0–3 mg
per mL) were harvested, and stored at 701C.
Statistical analysis Statistical analyses were performed using the
two-tailed, student t test or the paired t test. A p-value of less than
0.05 was considered statistically significant. All analyses were
performed using Statistical Analysis Software (SAS, Cary, North
Carolina).
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